title: Prevalence of deep vein thrombosis in acutely admitted ambulatory non-surgical intensive care unit patients.
abstract: BACKGROUND
  Data on prevalence rates of venous thromboembolism (VTE) in different patient populations are scarce. Most studies on this topic focus on older patients or patients with malignancies, immobilization or thrombophilia. Less is known about the VTE risk profile of non-surgical patients presenting with a variety of medical diseases of differing severity. Aim of the present study was to investigate VTE prevalence in a pospective cohort study of ambulatory medical intensive care unit patients within 24 h after acute admission.
  
  
  METHODS
  Prospective cohort study of 102 consecutive patients after acute admission to medical intensive care unit. Ultrasound compression sonography, APACHE-II-Scoring and laboratory examination was performed within 24 hours after admission.Possible determinants of a high risk of VTE were examined. In all patients with a confirmed diagnosis of DVT or suspicion of PE thoracic computer tomography (CT) was performed.
  
  
  RESULTS
  VTE was found in 7.8% out of 102 of patients, mean APACHE-II-Score was 14 (mortality risk of about 15%). Thrombus location was femoropopliteal in 5 patients, iliacal in 2 and peroneal in 1 patient. Five VTE patients had concomitant PE (62.5% of VTE, 4.9% of all patients). No predictors of prevalent VTE were identified from univariable regression analysis although relative risk was high in patients with a history of smoking (RR 3.40), immobility (RR 2.50), and elevated D-Dimer levels (RR 3.49).
  
  
  CONCLUSIONS
  Prevalent VTE and concomitant PE were frequent in acutely admitted ICU patients.
authors.affiliation: Department of Angiology, Asklepios Westklinikum Hamburg, Suurheid 20, 22559 Hamburg, Germany. h.lawall@asklepios.com.
authors.forename: Holger
authors.initials: H
authors.lastname: Lawall
authors.forename: Ralph
authors.initials: R
authors.lastname: Oberacker
authors.forename: Claudia
authors.initials: C
authors.lastname: Zemmrich
authors.forename: Peter
authors.initials: P
authors.lastname: Bramlage
authors.forename: Curt
authors.initials: C
authors.lastname: Diehm
authors.forename: Sebastian M
authors.initials: SM
authors.lastname: Schellong
mesh_terms: D018806:APACHE; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005858:Germany / Q000453:epidemiology; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007362:Intensive Care Units / Q000706:statistics & numerical data*; D008297:Male; D008875:Middle Aged; D010044:Outpatient Clinics, Hospital / Q000706:statistics & numerical data*; D010343:Patient Admission / Q000706:statistics & numerical data*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015995:Prevalence; D011446:Prospective Studies; D011655:Pulmonary Embolism / Q000188:drug therapy / Q000453:epidemiology; D012307:Risk Factors; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D054556:Venous Thromboembolism / Q000188:drug therapy / Q000453:epidemiology; D020246:Venous Thrombosis / Q000188:drug therapy / Q000453:epidemiology*
chemical_list: D000925:Anticoagulants; D005338:Fibrin Fibrinogen Degradation Products; D010975:Platelet Aggregation Inhibitors; C036309:fibrin fragment D; D006493:Heparin; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin